{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:16:17Z","timestamp":1792120577576,"version":"4.4.0"},"reference-count":68,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Long-term survivors of Hodgkin lymphoma (HL) experience several late adverse effects of treatment, with second malignant neoplasms (SMNs) and cardiovascular diseases (CVDs) being the leading causes of death in these patients. Other late effects have also been identified, such as pulmonary dysfunction, endocrinopathies (thyroid dysfunction, infertility), neck muscle atrophy, and persistent fatigue. HL survivors have two- to fourfold increased risks to develop SMNs and CVD compared with the general population. With respect to SMNs, radiotherapy is associated with 1.5- to 15-fold increased risk of solid malignancies. The relative risk (RR) of solid tumors increases steadily with increasing follow-up time from 5 to 15 years since radiotherapy, and remains elevated for at least 40 years. The RR of solid SMNs increases strongly with younger age at first treatment. Risks of lung, breast, and gastrointestinal (GI) cancers increase with higher radiation dose. Alkylating agent chemotherapy, especially procarbazine, does not only increase risk of leukemia but also of solid malignancies, in particular, cancers of the lung and GI tract. In contrast, gonadotoxic chemotherapy decreases the risk of radiation-associated breast cancer, through induction of premature menopause. Smoking appears to multiply the radiation- and chemotherapy-associated risks of lung cancer. Both radiotherapy and chemotherapy for HL may cause cardiovascular toxicity. Radiotherapy increases the risk of coronary heart disease, valvular heart disease, congestive heart failure (HF), and pericarditis, whereas anthracycline-containing chemotherapy increases the risks of HF and valvular heart disease. Cardiovascular toxicity following radiotherapy is usually observed from 5 to at least 35 years after therapy, whereas anthracycline-related toxicity is already observed during treatment, up to at least 25 years. The joint effects of anthracyclines, radiotherapy, and conventional cardiovascular risk factors (eg, hypertension, smoking, and physical inactivity) appear to be additive rather than multiplicative. HL survivors need lifelong risk-based screening for selected SMNs and CVDs. Furthermore, preventive strategies should include lifestyle and drug-based interventions to minimize exposure to conventional risk factors for cancer and CVD.<\/jats:p>","DOI":"10.1182\/asheducation-2016.1.323","type":"journal-article","created":{"date-parts":[[2016,12,2]],"date-time":"2016-12-02T16:05:27Z","timestamp":1480694727000},"page":"323-330","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":135,"title":["Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment"],"prefix":"10.1182","volume":"2016","author":[{"given":"Flora E.","family":"van Leeuwen","sequence":"first","affiliation":[{"name":"Division of Psychosocial Research and Epidemiology, Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea K.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Brigham and Women\u2019s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2019111704044974900_B1","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/cncr.24178","article-title":"Survival after Hodgkin lymphoma: causes of death and excess mortality in patients treated in 8 consecutive trials","volume":"115","author":"Favier","year":"2009","journal-title":"Cancer"},{"issue":"8","key":"2019111704044974900_B2","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1200\/JCO.2002.08.021","article-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin\u2019s disease treated at age 50 or younger","volume":"20","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111704044974900_B3","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.ejca.2010.02.010","article-title":"Mortality is persistently increased in Hodgkin\u2019s lymphoma survivors","volume":"46","author":"Kiserud","year":"2010","journal-title":"Eur J Cancer"},{"issue":"14","key":"2019111704044974900_B4","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/cncr.25053","article-title":"A population-based study of follow-up care for Hodgkin lymphoma survivors: opportunities to improve surveillance for relapse and late effects","volume":"116","author":"Hodgson","year":"2010","journal-title":"Cancer"},{"issue":"18","key":"2019111704044974900_B5","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin\u2019s disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704044974900_B6","doi-asserted-by":"crossref","first-page":"djv018","DOI":"10.1093\/jnci\/djv018","article-title":"Late morbidity and mortality in patients with Hodgkin\u2019s lymphoma treated during adulthood","volume":"107","author":"Matasar","year":"2015","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"2019111704044974900_B7","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1016\/S0959-8049(98)00269-X","article-title":"Socio-medical situation for long-term survivors of Hodgkin\u2019s disease: a survey of 459 patients treated at one institution","volume":"34","author":"Abrahamsen","year":"1998","journal-title":"Eur J Cancer"},{"issue":"4","key":"2019111704044974900_B8","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ijc.10981","article-title":"Health profiles in 5836 long-term cancer survivors","volume":"104","author":"Schultz","year":"2003","journal-title":"Int J Cancer"},{"issue":"26","key":"2019111704044974900_B9","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1505949","article-title":"Second cancer risk up to 40 years after treatment for Hodgkin\u2019s lymphoma","volume":"373","author":"Schaapveld","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111704044974900_B10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2013-10-532184","article-title":"Risk of multiple primary malignancies following treatment of Hodgkin lymphoma","volume":"124","author":"van Eggermond","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111704044974900_B11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"12","key":"2019111704044974900_B12","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1200\/JCO.2006.09.0936","article-title":"Long-term solid cancer risk among 5-year survivors of Hodgkin\u2019s lymphoma","volume":"25","author":"Hodgson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"2019111704044974900_B13","doi-asserted-by":"crossref","first-page":"dju207","DOI":"10.1093\/jnci\/dju207","article-title":"Risk of premature menopause after treatment for Hodgkin\u2019s lymphoma","volume":"106","author":"Swerdlow","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2019111704044974900_B14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.seminhematol.2016.05.008","article-title":"Hodgkin lymphoma: late effects of treatment and guidelines for surveillance","volume":"53","author":"Ng","year":"2016","journal-title":"Semin Hematol"},{"issue":"11","key":"2019111704044974900_B15","doi-asserted-by":"crossref","first-page":"e492","DOI":"10.1016\/S2352-3026(15)00153-2","article-title":"Cardiovascular disease after treatment for Hodgkin\u2019s lymphoma: an analysis of nine collaborative EORTC-LYSA trials","volume":"2","author":"Maraldo","year":"2015","journal-title":"Lancet Haematol"},{"issue":"3","key":"2019111704044974900_B16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1200\/JCO.2011.37.1989","article-title":"Premature ovarian failure and fertility in long-term survivors of Hodgkin\u2019s lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte Cohort Study","volume":"30","author":"van der Kaaij","year":"2012","journal-title":"J Clin Oncol"},{"issue":"19","key":"2019111704044974900_B17","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.2006.10.2020","article-title":"Gonadal function in males after chemotherapy for early-stage Hodgkin\u2019s lymphoma treated in four subsequent trials by the European Organisation for Research and Treatment of Cancer: EORTC Lymphoma Group and the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"25","author":"van der Kaaij","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111704044974900_B18","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1093\/annonc\/9.suppl_5.S147","article-title":"Quality of life assessment in Hodgkin\u2019s disease: a new comprehensive approach. First experiences from the EORTC\/GELA and GHSG trials. EORTC Llymphoma Cooperative Group. Goupe D\u2019Etude des Lymphomes de L\u2019Adulte and German Hodgkin Study Group","volume":"9","author":"Flechtner","year":"1998","journal-title":"Ann Oncol"},{"issue":"9","key":"2019111704044974900_B19","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00277-011-1274-4","article-title":"The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma survivors: a systematic review","volume":"90","author":"Oerlemans","year":"2011","journal-title":"Ann Hematol"},{"key":"2019111704044974900_B20","first-page":"411","article-title":"Cardiovascular and pulmonary late effects","volume-title":"Hodgkin Lymphoma: A Comprehensive Overview Hematologic Malignancies","author":"Aleman","year":"2014"},{"key":"2019111704044974900_B21","first-page":"375","article-title":"Second malignancy risk after treatment of Hodgkin lymphoma","volume-title":"Hodgkin Lymphoma: A Comprehensive Overview Hematologic Malignancies","author":"Hodgson","year":"2014"},{"key":"2019111704044974900_B22","article-title":"New malignancies following Hodgkin lymphoma, non-Hodgkin lymphoma, and myeloma","volume-title":"New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000","author":"Dores","year":"2006"},{"issue":"3","key":"2019111704044974900_B23","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1200\/JCO.2000.18.3.498","article-title":"Risk of second malignancy after Hodgkin\u2019s disease in a collaborative British cohort: the relation to age at treatment","volume":"18","author":"Swerdlow","year":"2000","journal-title":"J Clin Oncol"},{"issue":"16","key":"2019111704044974900_B24","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1200\/JCO.2002.09.038","article-title":"Second malignant neoplasms among long-term survivors of Hodgkin\u2019s disease: a population-based evaluation over 25 years","volume":"20","author":"Dores","year":"2002","journal-title":"J Clin Oncol"},{"issue":"23","key":"2019111704044974900_B25","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1200\/JCO.2003.11.059","article-title":"High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin\u2019s disease: report from the Late Effects Study Group","volume":"21","author":"Bhatia","year":"2003","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111704044974900_B26","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2011.38.8835","article-title":"Breast cancer risk after supradiaphragmatic radiotherapy for Hodgkin\u2019s lymphoma in England and Wales: a National Cohort Study","volume":"30","author":"Swerdlow","year":"2012","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111704044974900_B27","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-02-0634","article-title":"Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors","volume":"100","author":"Ng","year":"2002","journal-title":"Blood"},{"issue":"26","key":"2019111704044974900_B28","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1200\/JCO.2008.19.9174","article-title":"Breast cancer risk in female survivors of Hodgkin\u2019s lymphoma: lower risk after smaller radiation volumes","volume":"27","author":"De Bruin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"21","key":"2019111704044974900_B29","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1200\/JCO.2013.54.4601","article-title":"Breast cancer after chest radiation therapy for childhood cancer","volume":"32","author":"Moskowitz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111704044974900_B30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1056\/NEJM199001043220102","article-title":"Leukemia following Hodgkin\u2019s disease","volume":"322","author":"Kaldor","year":"1990","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111704044974900_B31","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin\u2019s disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"2019111704044974900_B32","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"issue":"13","key":"2019111704044974900_B33","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/jnci\/95.13.971","article-title":"Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin\u2019s disease","volume":"95","author":"van Leeuwen","year":"2003","journal-title":"J Natl Cancer Inst"},{"issue":"27","key":"2019111704044974900_B34","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO.2013.50.6832","article-title":"Stomach cancer risk after treatment for Hodgkin lymphoma","volume":"31","author":"Morton","year":"2013","journal-title":"J Clin Oncol"},{"issue":"10","key":"2019111704044974900_B35","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1093\/annonc\/mdu287","article-title":"Pancreatic cancer risk after treatment of Hodgkin lymphoma","volume":"25","author":"Dores","year":"2014","journal-title":"Ann Oncol"},{"issue":"2","key":"2019111704044974900_B36","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1667\/0033-7587(2003)159[0161:LCATFH]2.0.CO;2","article-title":"Lung cancer after treatment for Hodgkin\u2019s disease: focus on radiation effects","volume":"159","author":"Gilbert","year":"2003","journal-title":"Radiat Res"},{"issue":"8","key":"2019111704044974900_B37","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1093\/annonc\/mdt156","article-title":"Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma","volume":"24","author":"Maraldo","year":"2013","journal-title":"Ann Oncol"},{"issue":"6","key":"2019111704044974900_B38","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1200\/JCO.2001.19.6.1610","article-title":"Lung cancer after Hodgkin\u2019s disease: a nested case-control study of the relation to treatment","volume":"19","author":"Swerdlow","year":"2001","journal-title":"J Clin Oncol"},{"issue":"31","key":"2019111704044974900_B39","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1200\/JCO.2011.34.8268","article-title":"Second cancer risk after chemotherapy for Hodgkin\u2019s lymphoma: a collaborative British cohort study","volume":"29","author":"Swerdlow","year":"2011","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111704044974900_B40","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejcsup.2014.03.002","article-title":"Cardiovascular disease after cancer therapy","volume":"12","author":"Aleman","year":"2014","journal-title":"EJC Suppl"},{"issue":"17","key":"2019111704044974900_B41","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","article-title":"Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association.","volume":"128","author":"Lipshultz","year":"2013","journal-title":"Circulation"},{"issue":"12","key":"2019111704044974900_B42","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","article-title":"Treatment-related cardiotoxicity in survivors of childhood cancer","volume":"10","author":"Lipshultz","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"2019111704044974900_B43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1667\/RR1862.1","article-title":"Vascular damage as an underlying mechanism of cardiac and cerebral toxicity in irradiated cancer patients","volume":"174","author":"Stewart","year":"2010","journal-title":"Radiat Res"},{"issue":"2","key":"2019111704044974900_B44","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2353\/ajpath.2006.050409","article-title":"Ionizing radiation accelerates the development of atherosclerotic lesions in ApoE-\/- mice and predisposes to an inflammatory plaque phenotype prone to hemorrhage","volume":"168","author":"Stewart","year":"2006","journal-title":"Am J Pathol"},{"issue":"1","key":"2019111704044974900_B45","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ijrobp.2014.05.038","article-title":"Impact of cardiovascular counseling and screening in Hodgkin lymphoma survivors","volume":"90","author":"Dani\u00ebls","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2019111704044974900_B46","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1200\/JCO.2006.07.0805","article-title":"Screening for coronary artery disease after mediastinal irradiation for Hodgkin\u2019s disease","volume":"25","author":"Heidenreich","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111704044974900_B47","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1200\/JCO.2009.25.2627","article-title":"Evaluation of coronary artery disease by computed tomography angiography in patients treated for childhood Hodgkin\u2019s lymphoma","volume":"28","author":"K\u00fcpeli","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111704044974900_B48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijrobp.2014.01.021","article-title":"Prospective coronary heart disease screening in asymptomatic Hodgkin lymphoma patients using coronary computed tomography angiography: results and risk factor analysis","volume":"89","author":"Girinsky","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"2019111704044974900_B49","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/jnci\/djk029","article-title":"Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study","volume":"99","author":"Swerdlow","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"16","key":"2019111704044974900_B50","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1001\/jama.1993.03510160067031","article-title":"Factors affecting late mortality from heart disease after treatment of Hodgkin\u2019s disease","volume":"270","author":"Hancock","year":"1993","journal-title":"JAMA"},{"issue":"5","key":"2019111704044974900_B51","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2006-07-034405","article-title":"Late cardiotoxicity after treatment for Hodgkin lymphoma","volume":"109","author":"Aleman","year":"2007","journal-title":"Blood"},{"issue":"21","key":"2019111704044974900_B52","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1001\/jama.290.21.2831","article-title":"Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy","volume":"290","author":"Hull","year":"2003","journal-title":"JAMA"},{"issue":"8","key":"2019111704044974900_B53","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1080\/10428190802140873","article-title":"Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy","volume":"49","author":"Myrehaug","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111704044974900_B54","doi-asserted-by":"crossref","first-page":"djv008","DOI":"10.1093\/jnci\/djv008","article-title":"Risk of valvular heart disease after treatment for Hodgkin lymphoma","volume":"107","author":"Cutter","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2019111704044974900_B55","first-page":"S25","article-title":"A radiation dose-response relationship for risk of heart failure in survivors of Hodgkin lymphoma [abstract]","volume-title":"Radiother Oncol","author":"Aleman","year":"2016"},{"issue":"3","key":"2019111704044974900_B56","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"issue":"29","key":"2019111704044974900_B57","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"issue":"32","key":"2019111704044974900_B58","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.1200\/JCO.2014.56.7511","article-title":"Exercise and risk of major cardiovascular events in adult survivors of childhood Hodgkin lymphoma: a report from the childhood cancer survivor study","volume":"32","author":"Jones","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704044974900_B59","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019111704044974900_B60","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1748-717X-9-94","article-title":"Dosimetric advantages of a \u201cbutterfly\u201d technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin\u2019s lymphoma","volume":"9","author":"Voong","year":"2014","journal-title":"Radiat Oncol"},{"issue":"1","key":"2019111704044974900_B61","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijrobp.2015.01.013","article-title":"Minimizing late effects for patients with mediastinal Hodgkin lymphoma: deep inspiration breath-hold, IMRT, or both?","volume":"92","author":"Aznar","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2019111704044974900_B62","first-page":"A9269","article-title":"The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment","volume":"159","author":"Dekker","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"2019111704044974900_B63","unstructured":"National Comprehensive Cancer Network. Guidelines for monitoring for late effects in HL survivors. 2015. Version 2. Available at: http:\/\/wwwnccnorg\/professionals\/physician_gls\/pdf\/hodgkinspdf. Accessed April 2016."},{"key":"2019111704044974900_B64","unstructured":"Children\u2019s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers. Version 4.0. 2014. Available at: http:\/\/www.survivorshipguidelines.org. Accessed April 2016."},{"issue":"6","key":"2019111704044974900_B65","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.seminoncol.2013.09.004","article-title":"Risk-based health care, the cancer survivor, the oncologist, and the primary care physician","volume":"40","author":"McCabe","year":"2013","journal-title":"Semin Oncol"},{"issue":"13","key":"2019111704044974900_B66","doi-asserted-by":"crossref","first-page":"e621","DOI":"10.1016\/S1470-2045(13)70303-6","article-title":"Recommendations for breast cancer surveillance for female survivors of childhood, adolescent, and young adult cancer given chest radiation: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"14","author":"Mulder","year":"2013","journal-title":"Lancet Oncol"},{"issue":"35","key":"2019111704044974900_B67","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2014.58.5562","article-title":"Improving screening practices in childhood cancer survivors at risk for treatment-related heart failure","volume":"32","author":"Armenian","year":"2014","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111704044974900_B68","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/sj.bjc.6605215","article-title":"The UK national breast cancer screening programme for survivors of Hodgkin lymphoma detects breast cancer at an early stage","volume":"101","author":"Howell","year":"2009","journal-title":"Br J Cancer"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/323\/1249675\/hem088367.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2016\/1\/323\/1249675\/hem088367.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T09:05:18Z","timestamp":1573981518000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2016\/1\/323\/20984\/Longterm-risk-of-second-malignancy-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12,2]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2016.1.323","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,2]]}}}